Amylyx Pharmaceuticals Inc's total assets for Q3 2025 were $362.74M, an increase of 86.41% from the previous quarter. AMLX total liabilities were $30.75M for the fiscal quarter, a 15.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.